1971P Neuroendocrine (NE) expression profiling in non-castrate tumours is associated with poor therapy benefit and adverse clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients

Autor:	Montserrat Domenech, Leonardo Rodriguez-Carunchio, Andreu Prat, L. Ferrer-Mileo, Begoña Mellado, D. Pesántez, G. Castellano, Joan Carles, Mercedes Marín-Aguilera, M. Orrillo, Alejo Rodriguez-Vida, H.K. Oberoi, A. Font, Òscar Reig, Natalia Jiménez, S. Díaz, Núria Sala-González, Cristina Suarez
Rok vydání:	2020
Předmět:	Oncology Gene expression profiling medicine.medical_specialty Prostate cancer business.industry Internal medicine medicine Hematology Castration resistant medicine.disease business
Zdroj:	Annals of Oncology. 31:S1107
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.1363
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a6d3ce69fee996ac51357f3d92b18171 https://doi.org/10.1016/j.annonc.2020.08.1363 Zobrazit plný text záznamu